Privately-held Irish-American company Shorla Pharma has announced a partnership with Eversana to support the launch and commercialization of its oncology portfolio.
The partnership will initially focus on SH-111, a drug designed to treat T-cell leukemia, currently pending US Food and Drug Administration approval.
Under the terms of the agreement, Shorla maintains ownership of SH-111 as well as all financial, legal, regulatory, and manufacturing responsibilities for the product.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze